Sentences with phrase «transplanted cells grafted»

Not exact matches

«Finding the optimal conditions to avoid interfering with immune cells working to eradicate cancer while preventing graft rejection and GVHD is the holy grail of bone marrow transplant,» says Leo Luznik, M.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center.

A decade ago, he replicated the entire human leukemia disease process by introducing oncogenes into normal human blood cells, transplanting them into xenografts (special immune - deficient mice that accept human grafts) and watching leukemia develop — a motherlode discovery that has guided leukemia research ever since.

Historically, clinicians evaluating a patient for transplant have sought to identify donor cells that are perfectly matched to the patient's cell type, which is considered to be the optimal approach to help ensure successful outcomes and to minimize risk of graft - versus - host disease (GVHD), a serious and potentially life - threatening complication that occurs when the donated immune cells attack the patient's cells as foreign tissue.

On the flipside, targeting this growth factor or BCL - 2 could reduce NK cell numbers and offer potential therapies for immune disorders such as some types of autoimmune diseases, sepsis or graft versus host disease, a side effect of bone marrow transplants.

«Preventing graft - versus - host disease and relapse after transplant requires a difficult balance of eliminating the bad, overactive effector T cells, without suppressing the good, regulatory T cells,» said Kean, who is also an associate professor of pediatrics at the University of Washington School of Medicine and a member of the Fred Hutchinson Cancer Research Center.

«Given the serious threat of graft - versus - host disease, new approaches to make stem cell transplants safer for patients remain a critical unmet need,» said Dr. Leslie Kean, the trial's principal investigator and associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children's.

«Immunotherapy drug nearly eliminates severe acute graft - versus - host disease: Drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant.»

One of the biggest challenges for medical researchers studying the effectiveness of stem cell therapies is that transplants or grafts of cells are often rejected by the hosts.

A new test may reveal which patients will respond to treatment for graft versus host disease (GVHD), an often life - threatening complication of stem cell transplants (SCT) used to treat leukemia and other blood disorders, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and published online today in the journal Lancet Haematology and in print in the January issue.

Wartman has a chronic form of graft - versus - host disease (GVHD), a debilitating consequence of blood stem cell transplants.

Now, in a study recently published in the journal PLOS ONE, a team of scientists from VCU Massey Cancer Center have shown a genetic relationship between the reactivation of hCMV and the onset of graft - versus - host disease (GVHD), a potentially deadly condition in which the immune system attacks healthy tissue following a bone marrow or stem cell transplant.

To eliminate the problem for good, Faustman borrowed an idea from the transplant specialists, who have found that liver or spleen cells can «reeducate» a graft recipient's immune system to treat the graft as native tissue.

Given to the patient shortly before the transplant, the infusion of antibodies theoretically reduces the host's residual T cells, minimizing the risk of graft rejection while eliminating T cells from the donor to thwart GVHD.

The research team tested the hypothesis by transplanting cells onto the surface of mouse bone grafts and studying the cell behavior both in vivo — inside the animal — and in vitro — outside the body.

In some cases, the transplanted marrow launches an immune attack against the host's cells, a potentially lethal condition called graft - versus - host disease.

In patients with GVHD, newly transplanted T cells from the bone marrow graft attack the transplant recipient's body.

While both eye fields and EFTF - expressing pluripotent cells generated epidermis, forebrain, and olfactory tissue when grafted to the anterior neural plate, transplanted eye fields also formed muscle and head mesenchyme (Figure 4 and unpublished data).

Potentially everyone can benefit from gene modified T cells and there's no danger of graft versus host disease because it's not a transplant from another person.

Sorting stem cells before transplant helps lower the risk of graft - vs.

The only documented long - term complete remissions reported in multiple myeloma patients have occurred with allogeneic bone marrow transplantation, where a donor's blood stem cells (graft) are transplanted into the patient (host) with multiple myeloma.

For the other adult patients that might still benefit from a cord blood donor, either two cord blood units are combined for a single transplant, or more recently, there are some exciting new graft engineering technologies that are emerging to expand stem or progenitor cells in the laboratory before infusion or modify the cells in some way to make them more potent at the time of transplant.

But for blood cancer patients who receive donor hematopoietic stem cell transplants as part of their treatment, graft - versus - host disease (GVHD) often hampers their recovery.

Sorting stem cells before transplant helps lower risk of graft - vs.

Indeed, postmortems of some of the people who had previously received fetal cell transplants found evidence of the disease in some of the cells in the graft as though the protein involved in Parkinson's had caused disease in the transplant.

Procedures include purging of cancerous cells and purifying donor stem cells to minimize graft - versus - host disease (a serious side effect related to the use of donor cells for transplant).

Transplanted organs, tissues and cells are targets of the host immune response, that, in the absence of adequate immunesuppression, lead to graft loss.

Chloroquine Prevention Of Murine MHC Disparate Acute Graft - Versus - Host Disease Correlates With Inhibition Of Spleenic Response To CpG Oligodeoxynucleotides And Alterations In T Cell Cytokine Production, Biol Blood Marrow Transplant 8 (12): 648 - 55, 2002.

His research interest is graft - versus - host disease (GVHD), an immune complication after a donor stem cell transplant.

Interestingly, when we looked at the splenocytes in these mice and compared them to controls, we were not able to detect a significant difference in the numbers of Tregs, suggesting that in the transplant model, Tregs may be within the graft - infiltrating population where they could regulate infiltrating host T cells.

If these results are confirmed and one or more of these FLT3 - targeted drugs become approved by the FDA, testing for the FLT3 biomarker may eliminate the need for thousands of patients to undergo stem cell transplantation (each allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and other complications such as Graft vs. Host disease).

His research interest is graft - versus - host disease, an immune complication after a donor stem cell transplant.